Pharmaceutical

Rallybio and J&J collaborate to tackle maternal-foetal blood disorder

The collaboration pact will see Rallybio gaining a $6.6m equity investment from J&J to further a natural history study of FNAIT.

Apr 13, 2024 - 00:00
Rallybio and J&J collaborate to tackle maternal-foetal blood disorder
The collaboration pact will see Rallybio gaining a $6.6m equity investment from J&J to further a natural history study of FNAIT.
Read the original article

Tags:

Previous Article

FDA approves AstraZeneca’s FASENRA for asthma in children

Next Article

Carbon beads help restore healthy gut microbiome and reduce liver disease progre...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Flu activity gaining steam in the U.S. as vaccination rates lag

Flu activity gaining steam in the U.S. as vaccination r...

Nov 17, 2023

ASCO24: Can Ambrx’s novel ADC break into the metastatic breast cancer market?

ASCO24: Can Ambrx’s novel ADC break into the metastatic...

Jun 4, 2024

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Sanofi’s $17bn sale of Opella to US investors advances ...

Oct 22, 2024